Impaired neurotransmission caused by overexpression of α-synuclein in nigral dopamine neurons

Proceedings of the National Academy of Sciences of the United States of America

Volumn 109, Issue 9, 2012, Pages 3213-3219

  Lundblad, Martin ^a   Decressac, Mickael ^a   Mattsson, Bengt ^a   Björklund, Anders ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

Neurodegeneration; Synaptic transmission

Indexed keywords

ADENOVIRUS VECTOR; ALPHA SYNUCLEIN; DOPAMINE; POTASSIUM ION;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CORPUS STRIATUM; DOPAMINE RELEASE; DOPAMINE UPTAKE; DOPAMINERGIC NERVE CELL; FEMALE; INNERVATION; NERVE FIBER; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SYNAPSE;

ALPHA-SYNUCLEIN; ANIMALS; AXONS; CAUDATE NUCLEUS; DEPENDOVIRUS; DOPAMINE; DOPAMINE UPTAKE INHIBITORS; DOPAMINERGIC NEURONS; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTRODES, IMPLANTED; FEMALE; GENETIC VECTORS; HUMANS; MICROINJECTIONS; NOMIFENSINE; POTASSIUM; PUTAMEN; RATS; RATS, SPRAGUE-DAWLEY; RECOMBINANT FUSION PROTEINS; SUBSTANTIA NIGRA; SYNAPTIC TRANSMISSION; TRANSGENES; UP-REGULATION;

ADENO-ASSOCIATED VIRUS 6; RATTUS;

EID: 84857716290     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1200575109     Document Type: Article

References (32)

1. Cheng H-C, Ulane CM, Burke RE (2010) Clinical progression in Parkinson disease and the neurobiology of axons. Ann Neurol 67:715-725.
2. Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F (1973) Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci 20:415-455.
3. Riederer P, Wuketich S (1976) Time course of nigrostriatal degeneration in parkinson's disease. A detailed study of influential factors in human brain amine analysis. J Neural Transm 38:277-301.
4. Fearnley JM, Lees AJ (1991) Ageing and Parkinson's disease: Substantia nigra regional selectivity. Brain 114:2283-2301.
5. Ma SY, Röyttä M, Rinne JO, Collan Y, Rinne UK (1997) Correlation between neuromorphometry in the substantia nigra and clinical features in Parkinson's disease using disector counts. J Neurol Sci 151:83-87. (Pubitemid 27398014)
6. Scherman D, et al. (1989) Striatal dopamine deficiency in Parkinson's disease: Role of aging. Ann Neurol 26:551-557. (Pubitemid 19247232)
7. Lotharius J, Brundin P (2002) Impaired dopamine storage resulting from alpha-synuclein mutations may contribute to the pathogenesis of Parkinson's disease. Hum Mol Genet 11:2395-2407.
8. Baptista MJ, et al. (2003) Co-ordinate transcriptional regulation of dopamine synthesis genes by alpha-synuclein in human neuroblastoma cell lines. J Neurochem 85:957-968. (Pubitemid 36578627)
9. Larsen KE, et al. (2006) Alpha-synuclein overexpression in PC12 and chromaffin cells impairs catecholamine release by interfering with a late step in exocytosis. J Neurosci 26:11915-11922. (Pubitemid 44772102)
10. Nemani VM, et al. (2010) Increased expression of alpha-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis. Neuron 65:66-79.
11. Abeliovich A, et al. (2000) Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron 25:239-252. (Pubitemid 30316525)
12. Cabin DE, et al. (2002) Synaptic vesicle depletion correlates with attenuated synaptic responses to prolonged repetitive stimulation in mice lacking alpha-synuclein. J Neurosci 22:8797-8807. (Pubitemid 35379049)
13. Chadchankar H, Ihalainen J, Tanila H, Yavich L (2011) Decreased reuptake of dopamine in the dorsal striatum in the absence of α-synuclein. Brain Res 1382:37-44.
14. Kirik D, et al. (2002) Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system. J Neurosci 22:2780-2791. (Pubitemid 37465827)
15. Klein RL, King MA, Hamby ME, Meyer EM (2002) Dopaminergic cell loss induced by human A30P alpha-synuclein gene transfer to the rat substantia nigra. Hum Gene Ther 13:605-612. (Pubitemid 34264311)
16. Gorbatyuk OS, et al. (2008) The phosphorylation state of Ser-129 in human alphasynuclein determines neurodegeneration in a rat model of Parkinson disease. Proc Natl Acad Sci USA 105:763-768. (Pubitemid 351171782)
17. Chung CY, Koprich JB, Siddiqi H, Isacson O (2009) Dynamic changes in presynaptic and axonal transport proteins combined with striatal neuroinflammation precede dopaminergic neuronal loss in a rat model of AAV alpha-synucleinopathy. J Neurosci 29: 3365-3373.
18. Decressac M, Mattsson B, Lundblad M, Weikop P, Björklund A (2011) Progressive neurodegenerative and behavioural changes induced by AAV-mediated overexpression of α-synuclein in midbrain dopamine neurons. Neurobiol Dis, 10.1016/j. nbd.2011.12.013.
19. Venda LL, Cragg SJ, Buchman VL, Wade-Martins R (2010) α-Synuclein and dopamine at the crossroads of Parkinson's disease. Trends Neurosci 33:559-568.
20. Anwar S, et al. (2011) Functional alterations to the nigrostriatal system in mice lacking all three members of the synuclein family. J Neurosci 31:7264-7274.
21. Sidhu A, Wersinger C, Vernier P (2004) alpha-Synuclein regulation of the dopaminergic transporter: A possible role in the pathogenesis of Parkinson's disease. FEBS Lett 565:1-5. (Pubitemid 38595310)
22. Oaks AW, Sidhu A (2011) Synuclein modulation of monoamine transporters. FEBS Lett 585:1001-1006.
23. Yavich L, et al. (2005) Locomotor activity and evoked dopamine release are reduced in mice overexpressing A30P-mutated human alpha-synuclein. Neurobiol Dis 20:303-313. (Pubitemid 41476258)
24. Lam HA, et al. (2011) Elevated tonic extracellular dopamine concentration and altered dopamine modulation of synaptic activity precede dopamine loss in the striatum of mice overexpressing human α-synuclein. J Neurosci Res 89:1091-1102.
25. Sidhu A, Wersinger C, Vernier P (2004) Does alpha-synuclein modulate dopaminergic synaptic content and tone at the synapse? FASEB J 18:637-647. (Pubitemid 38451786)
26. Volles MJ, et al. (2001) Vesicle permeabilization by protofibrillar alpha-synuclein: Implications for the pathogenesis and treatment of Parkinson's disease. Biochemistry 40:7812-7819. (Pubitemid 32622972)
27. Conway KA, Rochet JC, Bieganski RM, Lansbury PT, Jr. (2001) Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct. Science 294:1346-1349. (Pubitemid 33063102)
28. Xu J, et al. (2002) Dopamine-dependent neurotoxicity of alpha-synuclein: A mechanism for selective neurodegeneration in Parkinson disease. Nat Med 8:600-606. (Pubitemid 34633438)
29. Paxinos G, Watson C (1986) The Rat Brain in Stereotaxic Coordinates (Academic Press, New York), 2nd Ed.
30. Hoffman AF, Gerhardt GA (1998) In vivo electrochemical studies of dopamine clearance in the rat substantia nigra: Effects of locally applied uptake inhibitors and unilateral 6-hydroxydopamine lesions. J Neurochem 70:179-189. (Pubitemid 28020842)
31. Zahniser NR, Larson GA, Gerhardt GA (1999) In vivo dopamine clearance rate in rat striatum: Regulation by extracellular dopamine concentration and dopamine transporter inhibitors. J Pharmacol Exp Ther 289:266-277. (Pubitemid 29156039)
32. Friedemann MN, Gerhardt GA (1992) Regional effects of aging on dopaminergic function in the Fischer-344 rat. Neurobiol Aging 13:325-332.